Q3 Cash Balance of $113.6M — Cash through Q3 2019
Continued progress on the advancement of key clinical programs including GITRL-Fc Phase 1 initiation
Management to Host Conference Call/Webcast this afternoon at 4:30 p.m. ET / 1:30 p.m. PT
REDWOOD CITY, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced third quarter financial results. As of September 30, 2017, cash, cash equivalents and short-term investments totaled $113.6 million.
"OncoMed remains committed to developing novel anti-cancer therapeutics to improve the lives of patients. With four clinical programs progressing, including the newly initiated Phase 1a study of GITRL-Fc (OMP-336B11), OncoMed is positioned to deliver value for both patients and our shareholders," commented Sunil Patel, Executive Vice President and Chief Financial Officer. "We look forward to upcoming clinical updates from our navicixizumab, rosmantuzumab and anti-TIGIT programs in 2018."
Read More: http://investor.shareholder.com/oncomed/releasedetail.cfm?ReleaseID=1046927
Comments are closed.